Literature DB >> 21029538

Hepatitis E virus infection in sheltered homeless persons, France.

Mamadou Kaba1, Philippe Brouqui, Hervé Richet, Sekené Badiaga, Pierre Gallian, Didier Raoult, Philippe Colson.   

Abstract

To determine the prevalence of hepatitis E virus (HEV) infection among sheltered homeless persons in Marseille, France, we retrospectively tested 490 such persons. A total of 11.6% had immunoglobulin (Ig) G and 2.5% had IgM against HEV; 1 person had HEV genotype 3f. Injection drug use was associated with IgG against HEV.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21029538      PMCID: PMC3294504          DOI: 10.3201/eid1611.091890

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Initially considered a leading cause of acute hepatitis in tropical and subtropical countries, hepatitis E virus (HEV) is endemic to industrialized countries (). Although substantial data indicate that HEV infection is a porcine zoonosis, more information is needed about the epidemiology and transmission of this virus in industrialized countries (–). Homeless persons are at higher risk than other persons for viral hepatitis (A, B, and C) because their lifestyle might include injection drug use (IDU) and poor hygiene (), but data on HEV prevalence among them are scarce (,). In Marseille in southeastern France, ≈1,500 persons are homeless (). Since 2000, shelter-based surveys have been conducted yearly to monitor infectious diseases in homeless persons (). This work determined the prevalence of HEV infection in this population.

The Study

The surveys were reviewed and approved by the Institutional Review Board (CCPPCRB99/76) (Comité de Protection des Personnes Sud-Méditerranée II; www.cpp-sudmed2.fr/) and the Ethics Committee of the Medical School, University of the Mediterranean, Marseille). Participating homeless persons were examined by a physician and interviewed by using a standardized questionnaire, and serum samples were collected from each participant for laboratory testing. Epidemiologic, clinical, and biologic data that were collected varied from 1 year to another. Serum samples collected from 490 homeless persons in 2003, 2005, and 2006 in 2 shelters in Marseille (Table A1) were tested retrospectively for immunoglobulin (Ig) G and IgM (EIAgen HEV kits; Adaltis Italia SpA, Rome, Italy) against HEV and for HEV RNA by using an in-house real-time reverse transcription–PCR specific for open reading frame 2 (). HEV RNA sequencing was performed when HEV RNA was detected, and genotype was assigned through phylogenetic analysis of open reading frame 2 partial sequences (). Serologic testing for hepatitis A, B, and C and for HIV were performed by using Axsym Abbott assays (Abbott Diagnostics Division, Wiesbaden, Germany). Statistical analysis was performed by using STATA version 10.1 software (StataCorp, College Station, TX, USA). Pearson χ2 test, Fisher exact test, Kruskal-Wallis test, or logistic regression model were used when appropriate.
Table A1

Univariate analysis of associations between variables and positive anti-HEV IgM and IgG testing in homeless persons, Marseilles, France, 2003, 2005, and 2006*

VariableTotal no. personsIgM testing positive
IgG testing positive
No. (%) personsp valueNo. (%) personsp value
Year of survey
20031818 (4.4)0.1121 (11.6)0.89
20052002 (1.0)22 (11.0)
2006
109
2 (1.8)


14 (12.8)

Sex
M47210 (2.1)0.0755 (11.6)0.65
F
18
2 (11.1)


2 (11.1)

Place of birth
North Africa1975 (2.5)0.9826 (13.2)0.94
France1635 (3.1)19 (11.7)
Eastern Europe762 (2.6)9 (11.8)
Sub-Saharan Africa2002 (10.0)
Europe (noneastern, except France)1501 (6.7)
French overseas departments and territories1200
Asia
7
0


0

History of injection drug use
Yes400.833 (75.0)0.006
No
172
8 (4.7)


19 (11.1)

History of blood transfusion
Yes2401.002 (8.3)0.34
No1582 (1.3)20 (12.7)
Do not know
17
0


0

History of surgery
Yes1032 (1.9)0.279 (8.7)0.20
No
96
0


13 (13.5)

History of dental care
Yes861 (1.2)0.618 (9.3)0.60
No
53
0


5 (9.4)

Body piercing
Yes1800.802 (11.1)0.58
No
154
2 (1.3)


16 (10.4)

Having tattoos
Yes401 (2.5)0.412 (5.0)0.16
No
132
1 (0.8)


16 (12.1)

History of owning a cat
Yes1000.631 (10.0)0.67
No
171
8 (4.7)


20 (11.7)

History of owning a dog
Yes81 (12.5)0.3100.36
No
173
7 (4.1)


21 (12.1)

History of pruritus
Yes1175 (4.3)0.3815 (12.8)0.39
No
172
5 (2.9)


19 (11.1)

Having scabies
Yes191 (5.3)0.406 (31.6)0.02
No
443
11 (2.5)


48 (10.8)

History of sexual intercourse with sex workers
Yes3300.684 (12.1)0.49
No
154
2 (1.3)


16 (10.4)

HAV serologic testing results
Positive892 (2.3)0.7311 (12.4)0.33
Negative
15
0


3 (20.0)

HBV serologic testing results indicating past or ongoing infection
Yes752 (2.7)0.299 (12.0)0.46
No
205
2 (1.0)


22 (10.7)

HCV serologic testing results
Positive2400.523 (12.5)0.52
Negative
437
12 (2.8)


49 (11.2)

HIV serologic testing results
Positive300.972 (66.7)0.03
Negative1752 (1.1)16 (9.1)

*HEV, hepatitis E virus; Ig, immunoglobulin; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus.

Mean ± SD age of homeless persons was 43 ± 14 years, and their mean ± SD duration of homelessness was 49 ± 84 months. Most (96.3%) were men and were born in North Africa (40.2%) or in France (33.3%) (Table A1). Previous or ongoing IDU was reported for 4/176 (2.3%). Overall prevalence of anti-HEV IgG and IgM was 11.6% (95% confidence interval [CI] 8.9%–14.8%) (57/490) and 2.5% (95% CI 1.3%–4.2%) (12/490), respectively. Mean optical density ratio (optical density/cutoff value) was 3.0 (range 1.1–6.9) and 2.0 (range 1.1–4.6) for IgG and IgM, respectively. Three (0.6%; 95% CI 0.1%–1.8%) homeless persons were concurrently positive for HEV IgM and IgG, whereas 9 (1.8%; 95% CI 0.8%–3.5%) were positive only for IgM and 54 (11%; 95% CI 8.4%–14.1%) were positive only for IgG. HEV RNA was detected in 1 homeless person, a 50-year-old man from Romania concurrently seronegative for HEV IgM and IgG and for hepatitis B and C viruses. He reported excessive alcohol intake but no IDU. HEV genotype was 3f (Figure), and sequence analysis showed 98% nt identity with sequences previously recovered from persons in Spain and France. Alanine aminotransferase (ALT) level had been assessed in only 2/12 HEV IgM–positive homeless persons and was elevated in 1 person (177 IU/L), in association with an increased γ-glutamyl transferase level (788 IU/L). Among the 19 homeless persons sampled in 2 different years, 1 seroconverted; he was seronegative for HEV IgM and IgG in 2005 then positive in 2006 (optical density ratio 1.14 and 4.3, respectively). Results of HEV RNA testing were negative in both serum samples, and ALT level had not been tested.
Figure

Phylogenetic tree based on partial nucleotide sequences (275 bp) corresponding to the 5′-end open reading frame 2 region of the hepatitis E virus (HEV) genome. Phylogenetic analysis included HEV sequence recovered in the present study (black circle, boldface and underlined; GenBank accession no. FJ71877) and sequences corresponding to the HEV sequences hits with the highest BLASTn score (http://blast.ncbi.nlm.nih.gov) to this sequence (black triangles), previously recovered in our laboratory (boldface), and of previously determined genotypes and subtypes () (in parentheses). Shading indicates sequences previously isolated in our laboratory. Bootstrap values >60% of 1,000 resamplings of the data are indicated. Avian HEV sequence AY043166 was used as an outgroup. The names of HEV sequences are labeled as follows: GenBank accession no., host, and country of origin where recovered. Scale bar indicates number of nucleotide substitutions per site.

Phylogenetic tree based on partial nucleotide sequences (275 bp) corresponding to the 5′-end open reading frame 2 region of the hepatitis E virus (HEV) genome. Phylogenetic analysis included HEV sequence recovered in the present study (black circle, boldface and underlined; GenBank accession no. FJ71877) and sequences corresponding to the HEV sequences hits with the highest BLASTn score (http://blast.ncbi.nlm.nih.gov) to this sequence (black triangles), previously recovered in our laboratory (boldface), and of previously determined genotypes and subtypes () (in parentheses). Shading indicates sequences previously isolated in our laboratory. Bootstrap values >60% of 1,000 resamplings of the data are indicated. Avian HEV sequence AY043166 was used as an outgroup. The names of HEV sequences are labeled as follows: GenBank accession no., host, and country of origin where recovered. Scale bar indicates number of nucleotide substitutions per site. The prevalence of HEV IgG or IgM in homeless persons did not differ by year of survey; sex; place of birth; or serologic status for hepatitis A, B, or C viruses (Table A1). In addition, mean age, duration of homelessness, and ALT, aspartate aminotransferase, and γ-glutamyl transferase levels did not differ among homeless persons who were positive or negative for HEV antibodies (Table). In the univariate analysis, previous or ongoing IDU (3/4 vs. 19/172; p = 0.006), HIV seropositivity (2/3 vs. 16/183; p = 0.03), and having scabies (6/20 vs. 48/462; p = 0.02) were significantly associated with HEV IgG. In multivariate analysis that used variables that were statistically significant in the univariate analysis as covariates, only IDU was independently associated with anti-HEV IgG (adjusted odds ratio 26.3, 95% CI 2.5–267.1; p = 0.006).
Table

Age, duration of homelessness, and liver biochemical test results for 490 homeless persons, Marseilles, France, 2003, 2005, and 2006*

VariableHEV IgM
HEV IgG
PositiveNegativep valuePositiveNegativep value
Age, y, mean ± SD37 ± 1243 ± 140.1345 ± 1543 ± 140.24
Duration of homelessness, mo, mean ± SD39 ± 3849 ± 850.3648 ± 7849 ± 850.28
Liver biochemical tests,† mean ± SD, IU/L
Alanine aminotransferase levels‡93 ± 11932 ± 310.9936 ± 3232 ± 330.49
Aspartate aminotransferase levels§49 ± 5434 ± 430.9934 ± 3234 ± 440.79
γ-Glutamyl transferase¶401 ± 54765 ± 1370.9276 ± 13668 ± 1470.44

*HEV, hepatitis E virus; Ig, immunoglobulin.
†Assessed only in 2005 for 209 homeless persons.
‡Data missing for 11 persons.
§Data missing for 10 persons.
¶Data missing for 9 persons.

*HEV, hepatitis E virus; Ig, immunoglobulin.
†Assessed only in 2005 for 209 homeless persons.
‡Data missing for 11 persons.
§Data missing for 10 persons.
¶Data missing for 9 persons.

Conclusions

We found that 11.6% (95% CI 8.9%–14.8%) of homeless persons in Marseille were positive for HEV IgG, whereas 2.6% (95% CI 1.3%–4.2%) had HEV IgM or HEV RNA, indicating recent or ongoing HEV infection. The HEV IgG prevalence is similar to that previously found () in homeless persons in Los Angeles, California, USA (13.5%), and much lower than that found in 98 homeless children in Cochabamba, Bolivia (66.3%) (). This prevalence falls between seroprevalences recently assessed among blood donors in northern (3.2%) and southwestern (16.6%) France (,). These comparisons should take into account the use of different serologic assays, in addition to differences in epidemiologic settings. Indeed, substantial differences have been observed regarding the performances of some HEV IgG tests (). Moreover, the sensitivity and specificity of the HEV IgG assay used in our study have not been previously evaluated, which warrants a cautious interpretation of the results. A preliminary study conducted in 2008 of 194 blood donors in Marseille with the same assay as that used in the present study found that the prevalence of HEV IgG was 9% (P. Gallian, unpub. data), which is similar to the seroprevalence we found in homeless persons. The HEV IgM assay we used showed good performance in patients with HEV genotype 3 infections in reference to PCR testing (). Thus, sensitivity, specificity, and negative predictive value were 90%, 100%, and 98.8%, respectively. In addition, sensitivities and specificities of this test and of the HEV IgM ELISA 3.0 (MP Diagnostics, Singapore) did not differ significantly. Although based on a small subset of homeless persons, our finding of the association of IDU with serologic results indicating past HEV infection is intriguing. This result is surprising because the proportion of IDUs in our homeless population was low (2.3%) and much lower than proportions previously reported (9%–83% (–). HEV IgG prevalence of 2.2%–62% has been described in IDUs, but a significant difference with the control group was found in only 2 of these studies (–). HEV IgG prevalence in Sweden was 62% (21/34) in patients who acquired acute hepatitis B through IDU compared with 25% (9/36) in patients with sexually acquired hepatitis B (p<0.005) (). Moreover, in Italy, the prevalence was 5.4% (16/179) in IDUs compared with 2.6% (49/1,889) in the general population (p<0.00001) (). In summary, our data indicate that HEV infection occurs in homeless persons, and further studies are needed to determine whether IDU is responsible for HEV transmission.
  15 in total

1.  A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries.

Authors:  Richard Bendall; Vic Ellis; Samreen Ijaz; Rachel Ali; Harry Dalton
Journal:  J Med Virol       Date:  2010-05       Impact factor: 2.327

Review 2.  Hepatitis E indigenous to economically developed countries: to what extent a zoonosis?

Authors:  Chong Gee Teo
Journal:  Curr Opin Infect Dis       Date:  2006-10       Impact factor: 4.915

Review 3.  Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis.

Authors:  Ling Lu; Chunhua Li; Curt H Hagedorn
Journal:  Rev Med Virol       Date:  2006 Jan-Feb       Impact factor: 6.989

4.  The high rate of antibodies to hepatitis E virus in young, intravenous drug-abusers with acute hepatitis B-virus infection in a Swedish community: a study of hepatitis markers in individuals with intravenously or sexually acquired hepatitis B-virus infection.

Authors:  S P Sylvan
Journal:  Scand J Infect Dis       Date:  1998

5.  Hepatitis E virus infection in north-east Italy: serological study in the open population and groups at risk.

Authors:  G Gessoni; F Manoni
Journal:  J Viral Hepat       Date:  1996-07       Impact factor: 3.728

6.  High prevalence of hepatitis E antibodies among Danish prisoners and drug users.

Authors:  Peer B Christensen; Ronald E Engle; Svend Erik H Jacobsen; Henrik B Krarup; Jørgen Georgsen; Robert H Purcell
Journal:  J Med Virol       Date:  2002-01       Impact factor: 2.327

Review 7.  [Prevalence of infections by hepatitis B, C, D and E viruses in Bolivia].

Authors:  P León; E Venegas; L Bengoechea; E Rojas; J A López; C Elola; J M Echevarría
Journal:  Rev Panam Salud Publica       Date:  1999-03

8.  Seroreactivity to hepatitis E virus in areas where the disease is not endemic.

Authors:  D L Thomas; P O Yarbough; D Vlahov; S A Tsarev; K E Nelson; A J Saah; R H Purcell
Journal:  J Clin Microbiol       Date:  1997-05       Impact factor: 5.948

9.  Prevalence study of antibody to ratborne pathogens and other agents among patients using a free clinic in downtown Los Angeles.

Authors:  Heather M Smith; Roshan Reporter; Michael P Rood; Andrea J Linscott; Laurene M Mascola; Wayne Hogrefe; Robert H Purcell
Journal:  J Infect Dis       Date:  2002-11-01       Impact factor: 5.226

10.  Prevalence of anti-hepatitis E virus antibodies in French blood donors.

Authors:  Annie Boutrouille; Labib Bakkali-Kassimi; Catherine Crucière; Nicole Pavio
Journal:  J Clin Microbiol       Date:  2007-04-25       Impact factor: 5.948

View more
  10 in total

Review 1.  The health of homeless people in high-income countries: descriptive epidemiology, health consequences, and clinical and policy recommendations.

Authors:  Seena Fazel; John R Geddes; Margot Kushel
Journal:  Lancet       Date:  2014-10-25       Impact factor: 79.321

Review 2.  Chronic hepatitis e virus infection and treatment.

Authors:  Nassim Kamar; Jacques Izopet; Harry R Dalton
Journal:  J Clin Exp Hepatol       Date:  2013-05-25

Review 3.  Hepatitis E virus infection.

Authors:  Nassim Kamar; Harry R Dalton; Florence Abravanel; Jacques Izopet
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

Review 4.  Autochthonous hepatitis e virus infections: a new transfusion-associated risk?

Authors:  Jens Dreier; David Juhl
Journal:  Transfus Med Hemother       Date:  2013-12-30       Impact factor: 3.747

5.  Hepatitis e virus infection in sheltered homeless persons, france.

Authors:  Sylvie Larrat; Stéphanie Gaillard; Monique Baccard; Lionel Piroth; Patrice Cacoub; Stanislas Pol; Christian Perronne; Fabrice Carrat; Patrice Morand
Journal:  Emerg Infect Dis       Date:  2012-06       Impact factor: 6.883

6.  Prevalence of HAV Ab, HEV (IgG), HSV2 IgG, and Syphilis Among Sheltered Homeless Adults in Tehran, 2012.

Authors:  Fatemeh Jahanbakhsh; Fahimeh Bagheri Amiri; Abbas Sedaghat; Noushin Fahimfar; Ehsan Mostafavi
Journal:  Int J Health Policy Manag       Date:  2018-03-01

7.  Hepatitis E virus seroprevalence and determinants in various study populations in the Netherlands.

Authors:  C J Alberts; M F Schim van der Loeff; S Sadik; F R Zuure; E J A J Beune; M Prins; M B Snijder; S M Bruisten
Journal:  PLoS One       Date:  2018-12-17       Impact factor: 3.240

Review 8.  Mobile populations across the Mediterranean Sea and beyond: travel medicine, mass gathering medicine and homeless health.

Authors:  P Gautret; B Pradines; Z A Memish; C Sokhna; P Parola
Journal:  New Microbes New Infect       Date:  2018-05-31

9.  Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States.

Authors:  Ludi Koning; Michael R Charlton; Suzan D Pas; Julie K Heimbach; Albert D M E Osterhaus; Kymberly D Watt; Harry L A Janssen; Robert J de Knegt; Annemiek A van der Eijk
Journal:  BMC Infect Dis       Date:  2015-09-02       Impact factor: 3.090

10.  Hepatitis E virus among persons who inject drugs, San Diego, California, USA, 2009-2010.

Authors:  Reena Mahajan; Melissa G Collier; Saleem Kamili; Jan Drobeniuc; Jazmine Cuevas-Mota; Richard S Garfein; Eyasu Teshale
Journal:  Emerg Infect Dis       Date:  2013-10       Impact factor: 6.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.